Cystatin C as a marker of renal function is affected by HIV replication leading to an underestimation of kidney function in HIV patients

Antiviral Therapy

Volumn 13, Issue 8, 2008, Pages 1091-1095

  Mauss, Stefan ^a   Berger, Florian ^a   Kuschak, Dieter ^b   Henke, Julia ^a   Hegener, Petra ^a   Wolf, Eva ^c   Schouseil, Stephan ^b   Schmutz, Guenther ^a  

^a Center for HIV and Hepatogastroenterology   (Germany)

^b Medical Laboratories Duesseldort   (Germany)

^c MUC Research GmbH and MVZ Karlsplatz   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CREATININE; CYSTATIN C; VIRUS RNA;

ADULT; AGED; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; CREATININE BLOOD LEVEL; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; VIRUS INHIBITION; VIRUS LOAD; VIRUS REPLICATION;

ADULT; AGED; BIOLOGICAL MARKERS; CYSTATIN C; FEMALE; HIV INFECTIONS; HUMANS; KIDNEY; MALE; MIDDLE AGED; VIRUS REPLICATION;

EID: 58149485465     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Mocroft A, Kirk O, Gatell J, et al. Chronic renal failure among HIV-1-infected patients. AIDS 2007; 21:1119-1127.
2. Perrone RD, Madias NE, Levey AS. Serum creatinine as an index of renal function: new insights into old concepts. Clin Chem 1992; 38:1933-1953.
3. Dharnidharka VR, Kwon C, Stevens G. Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. Am J Kidney Dis 2002; 40:221-226.
4. Odden MC, Scherzer R, Bacchetti P, et al. Cystatin C level as a marker of kidney function in human immunodeficiency virus infection. Arch Intern Med 2007; 167:2213-2219.
5. Galteau MM, Guyon M, Gueguen R, Siest G. Determination of serum cystatin C: biological variation and reference values. Clin Chem Lab Med 2001; 39:850-857.
6. Grubb A, Nyman U, Björk J, et al. Simple cystatin C-based prediction equations for glomerular filtration rate compared with the modification of diet in renal disease prediction equation for adults and the Schwartz and the CounahanBarratt prediction equations for children. Clin Chem 2005; 51:1420-1431.
7. Westhuyzen J. Cystatin C: a promising marker and predictor of impaired renal function. Ann Clin Lab Sci 2006; 36:387-394.
8. Stevens LA, Coresh J, Schmid CH, et al. Estimating GFR using serum cystatin C alone and in combination with serum creatinine: a pooled analysis of 3,418 individuals with CKD. Am J Kidney Dis 2008; 51:395-406.
9. Bartels H, Böhmer M, Heierli C. Serum creatinine determination without protein precipitation. Clin Chim Acta 1972; 37:193-197.
10. Simonsen O, Grubb A, Thysell H. The blood serum concentration of cystatin C (gamma-trace) as a measure of the glomerular filtration rare. Scand J Clin Lab Invest 1985; 45:97-101.
11. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 1999; 130:461-470.
12. Levey AS, Greene T, Kusek JW, Beck GJ. A simplified equation to predict glomerular filtration rate from serum creatinine. J Am Soc Nephrol. 2000; 11:Abstract A0828.
13. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16:31-41.
14. Levey AS, Coresh J, Balk E, et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 2003; 139:137-147.
15. Mauss S, Berger F, Schmutz G. Antiretroviral therapy with tenofovir is associated with mild renal dysfunction. AIDS 2005; 19:93-95.
16. Jaroszewicz J, Wiercinska-Drapalo A, Lapinski TV, Prokopowicz D, Rogalska M, Parfieniuk A. Does HAART improve renal function? An association between serum cystatin C concentration, HIV viral load and HAART duration. Antivir Ther 2006; 11:641-645.
17. Jones CY, Jones CA, Wilson IB, et al. Cystatin C and creatinine in an HIV cohort: The nutrition for healthy living study. Am J Kidney Dis 2008; 51:914-924.
18. Cimerman N, Brguljan PM, Krasovec M, Suskovic S, Kos J. Serum cystatin C, a potent inhibitor of cysteine proteinases, is elevated in asthmatic patients. Clin Chim Acta 2000; 300:83-95.
19. Singh D, Whooley MA, Ix JH, Ali S, Shlipak MG. Association of cystatin C and estimated GFR with inflammatory biomarkers: the Heart and Soul Study. Nephrol Dial Transplant 2007; 22:1087-1092.
20. Samouiliclou EC, Grapsa E. Relationship of serum cystatin C with C-reactive protein and apolipoprotein A1 in patients on hemodialysis. Ren Fail 2008; 30:711-715.
21. Fux CA, Simcock M, Wolbers M, et al. Tenofovir use is associated with a reduction in calculated glomerular filtration rates in the Swiss HIV Cohort Study. Antivir Ther 2007; 12:1165-1173.
22. Cassetti I, Madruga JV, Suleiman JM, et al. The safety and efficacy of tenofovir DF in combination with lamivudine and efavirenz through 6 years in antiretroviral-naive HIV-1-infected patients. HIV Clin Trials 2007; 8:164-172.
23. Nelson MR, Katlama C, Montaner JS, et al. The safety of tenofovir diso roxil fumarate for the treatment of HIV infection in adults: the first 4 years. AIDS 2007; 21:1273-1281.